Direct comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profiles for blood sugar, weight, and cardiometabolic outcomes.
Key findingDirect comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profi
What the researchers found
Direct comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profiles for blood sugar, weight, and cardiometabolic outcomes.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
18 months of follow-up. Compared semaglutide (GLP-1 RA) vs. empagliflozin (SGLT2 inhibitor). Specific outcome data not detailed in abstract.
How the study worked
In publication.
Who was studied
Adults with uncontrolled type 2 diabetes treated with semaglutide or empagliflozin
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).
Cureus, 17(5), e83416
Citation
Aristizabal-Colorado, David; Vernaza Trujillo, David Alexander; Sierra Castillo, Santiago; Rivera Martinez, Wilfredo Antonio; Badiel, Marisol; Abreu Lomba, Alin. (2025). Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).. Cureus, 17(5), e83416. https://doi.org/10.7759/cureus.83416